Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) will be reporting earnings this Thursday after the bell. Here’s what to expect.

Tandem Diabetes beat analysts’ revenue expectations by 1.5% last quarter, reporting revenues of $240.7 million, up 8.5% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates and full-year revenue guidance meeting analysts’ expectations.

Is Tandem Diabetes a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Tandem Diabetes’s revenue to decline 3.3% year on year to $236 million, a reversal from the 31.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.34 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tandem Diabetes has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Tandem Diabetes’s peers in the healthcare technology segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 49.2%, beating analysts’ expectations by 3.3%, and GoodRx reported flat revenue, topping estimates by 1.1%. Hims & Hers Health traded down 3.5% following the results.

Read our full analysis of Hims & Hers Health’s results here and GoodRx’s results here.

Investors in the healthcare technology segment have had steady hands going into earnings, with share prices flat over the last month. Tandem Diabetes is up 2.4% during the same time and is heading into earnings with an average analyst price target of $20.64 (compared to the current share price of $15.37).

P.S. In tech investing, "Gorillas" are the rare companies that dominate their markets—like Microsoft and Apple did decades ago. Today, the next Gorilla is emerging in AI-powered enterprise software. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.